CARDIoGRAM

CARDIoGRAM
Name	CARDIoGRAM
Formation	2008
Type	Consortium
Purpose	Genetic association studies of coronary artery disease and myocardial infarction
Headquarters	Europe
Members	Multiple academic institutions and biobanks

CARDIoGRAM

CARDIoGRAM was a large-scale international research consortium established to identify genetic loci associated with coronary artery disease and myocardial infarction through genome-wide association studies and meta-analyses. The consortium brought together investigators, cohorts, and biobanks from diverse institutions to increase statistical power for detecting common and low-frequency variants influencing cardiovascular risk. Its work integrated genetic epidemiology, statistical genetics, and clinical phenotyping to produce widely cited findings that informed downstream studies in cardiovascular biology and precision medicine.

Overview

The consortium assembled investigators from major centers and projects including University of Cambridge, Harvard Medical School, Imperial College London, University of Oxford, Karolinska Institutet, and McGill University alongside biobanks such as UK Biobank and cohorts including the Framingham Heart Study, Atherosclerosis Risk in Communities Study, European Prospective Investigation into Cancer and Nutrition, Rotterdam Study, and Multi-Ethnic Study of Atherosclerosis. Leadership and working groups involved researchers affiliated with organizations like Wellcome Trust, National Institutes of Health, European Commission, Max Planck Society, and Helmholtz Association. CARDIoGRAM organized consortia-level working groups, steering committees, and phenotype harmonization teams to coordinate multi-study analyses across populations from United Kingdom, United States, Sweden, Netherlands, Germany, Finland, Canada, and Italy.

Research Consortium and Objectives

The principal objective was to map genetic susceptibility to coronary artery disease and myocardial infarction by aggregating genome-wide association data from case-control and cohort studies. Secondary objectives included fine-mapping loci, assessing biological pathways, and enabling translational research into drug targets and biomarker discovery. The consortium aimed to bridge connections with pharmaceutical and translational entities such as GlaxoSmithKline, Pfizer, AstraZeneca, and academic translational centers at Broad Institute and Wellcome Sanger Institute. Oversight and ethics engagement referenced standards from bodies including World Health Organization and regional research ethics committees in institutions like University College London Hospital and Massachusetts General Hospital.

Methods and Data Cohorts

CARDIoGRAM used meta-analysis of genome-wide association studies employing platforms and pipelines developed at centers like Illumina-based genotyping facilities and imputation against reference panels such as those from the 1000 Genomes Project and Haplotype Reference Consortium. Analytical methods incorporated logistic regression, fixed-effects and random-effects meta-analysis, conditional analyses, and Bayesian fine-mapping approaches that were applied across datasets from consortia partners including CARDIoGRAMplusC4D collaborators and related efforts such as GIANT Consortium and DIAGRAM Consortium. Cohorts contributing phenotype data included long-term prospective studies like Nurses' Health Study, Health Professionals Follow-up Study, and registry-based resources such as Danish National Patient Registry and Swedish National Patient Register. Quality control, population stratification correction, and replication in independent samples involved statistical groups at University of Michigan, University of Helsinki, and Brigham and Women's Hospital.

Key Findings and Publications

Major publications reported identification of numerous loci associated with coronary artery disease and myocardial infarction, implicating pathways related to lipid metabolism, inflammation, vascular remodeling, and platelet biology. Landmark papers linked variants at loci near genes such as those studied at Stanford University, University of Pennsylvania, and Yale University laboratories and were published in high-profile journals including Nature Genetics, The Lancet, and European Heart Journal. Results intersected with functional genomics efforts at institutes such as Broad Institute, Salk Institute, and Cold Spring Harbor Laboratory to prioritize candidate genes and regulatory mechanisms. CARDIoGRAM outputs informed subsequent Mendelian randomization studies from groups at University of Bristol and Karolinska Institutet and guided experimental validation in model systems at Massachusetts Institute of Technology and Max Planck Institute for Heart and Lung Research.

Impact on Clinical Practice and Genetics

Findings from the consortium contributed evidence used by guideline committees and expert panels at organizations such as European Society of Cardiology, American College of Cardiology, and American Heart Association to contextualize genetic risk factors within cardiovascular prevention frameworks. Genetic loci identified influenced target nomination pipelines in pharmaceutical research at companies like Regeneron Pharmaceuticals and Novartis and underpinned commercial efforts in polygenic risk scoring pursued by entities affiliated with 23andMe and deCODE genetics. The results catalyzed translational projects in precision cardiology at academic health systems including Cleveland Clinic and Mayo Clinic and informed risk prediction, biomarker development, and mechanistic studies at translational centers such as Scripps Research.

Collaborations and Funding

CARDIoGRAM operated through collaborative networks connecting academic centers, national cohorts, and industry partners, with funding and in-kind support from agencies and foundations including European Research Council, National Heart, Lung, and Blood Institute, Wellcome Trust, British Heart Foundation, and philanthropic donors associated with institutions like Johns Hopkins University. Data sharing and collaborative agreements involved legal and ethical frameworks familiar to partners including European Molecular Biology Laboratory and national biobank consortia. International collaborations extended to research groups in China, Japan, Australia, Brazil, and South Africa, enabling broader ancestral representation and follow-up work by regional institutes such as Peking University, University of Tokyo, University of Melbourne, University of São Paulo, and University of Cape Town.

Category:Genetics research consortia